Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma
Ramucirumab is a fully humanized monoclonal antibody targeting the extracellular domain of the VEGF receptor 2. It prevents ligand binding to VEGF receptor 2 and receptor-mediated pathway activation in endothelial cells. After promising Phase I trial results in a variety of tumor types, two pivotal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
02 Jun 2015
|
| In: |
Expert review of anticancer therapy
Year: 2015, Volume: 15, Issue: 6, Pages: 607-614 |
| ISSN: | 1744-8328 |
| DOI: | 10.1586/14737140.2015.1052412 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1586/14737140.2015.1052412 Verlag, Volltext: https://doi.org/10.1586/14737140.2015.1052412 
|
| Author Notes: | Ralf-Dieter Hofheinz and Sylvie Lorenzen |
MARC
| LEADER | 00000caa a2200000 4500 | ||
|---|---|---|---|
| 001 | 1566888980 | ||
| 003 | DE-627 | ||
| 005 | 20230426064444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180105s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1586/14737140.2015.1052412 |2 doi | |
| 035 | |a (DE-627)1566888980 | ||
| 035 | |a (DE-576)496888986 | ||
| 035 | |a (DE-599)BSZ496888986 | ||
| 035 | |a (OCoLC)1340985647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma |c Ralf-Dieter Hofheinz and Sylvie Lorenzen |
| 264 | 1 | |c 02 Jun 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.01.2018 | ||
| 520 | |a Ramucirumab is a fully humanized monoclonal antibody targeting the extracellular domain of the VEGF receptor 2. It prevents ligand binding to VEGF receptor 2 and receptor-mediated pathway activation in endothelial cells. After promising Phase I trial results in a variety of tumor types, two pivotal placebo-controlled Phase III trials conducted in patients with pretreated metastatic esophagogastric adenocarcinoma demonstrated significant clinical activity regarding the prolongation of overall survival both as monotherapy (REGARD study) and in combination with paclitaxel (RAINBOW study). Currently, ramucirumab is being investigated in the first-line treatment of esophagogastric adenocarcinoma in combination with capecitabine and cisplatin in a Phase III trial (RAINFALL). | ||
| 650 | 4 | |a anti-angiogenic treatment | |
| 650 | 4 | |a gastroesophageal cancer | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a ramucirumab | |
| 650 | 4 | |a second-line therapy | |
| 700 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d Abingdon, Oxon : Taylor & Francis, 2001 |g 15(2015), 6, Seite 607-614 |h Online-Ressource |w (DE-627)355690446 |w (DE-600)2090850-7 |w (DE-576)398100047 |x 1744-8328 |7 nnns |a Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g number:6 |g pages:607-614 |g extent:8 |a Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1586/14737140.2015.1052412 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1586/14737140.2015.1052412 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180105 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1566888980 |e 2991693215 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1566888980","relHost":[{"origin":[{"dateIssuedKey":"2001","publisherPlace":"Abingdon, Oxon ; London","publisher":"Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"2001-"}],"part":{"pages":"607-614","volume":"15","issue":"6","year":"2015","extent":"8","text":"15(2015), 6, Seite 607-614"},"pubHistory":["1.2001 -"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinomaExpert review of anticancer therapy","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Expert review of anticancer therapy","title":"Expert review of anticancer therapy"}],"note":["Gesehen am 01.09.15"],"id":{"issn":["1744-8328"],"zdb":["2090850-7"],"eki":["355690446"]},"recId":"355690446"}],"id":{"eki":["1566888980"],"doi":["10.1586/14737140.2015.1052412"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Ralf-Dieter Hofheinz and Sylvie Lorenzen"]},"physDesc":[{"extent":"S.8"}],"person":[{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","role":"aut","roleDisplay":"VerfasserIn","given":"Ralf-Dieter"},{"roleDisplay":"VerfasserIn","given":"Sylvie","family":"Lorenzen","display":"Lorenzen, Sylvie","role":"aut"}],"language":["eng"],"note":["Gesehen am 05.01.2018"],"origin":[{"dateIssuedDisp":"02 Jun 2015","dateIssuedKey":"2015"}],"title":[{"title":"Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma","title_sort":"Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma"}]} | ||
| SRT | |a HOFHEINZRARAMUCIRUMA0220 | ||